RE:RE:With many smaller mj players facing major headwinds latelyThat would certainly be a bold move QC1, but would it leave them exposed with the fluctuations in this crazy industry.
I am very interested in Dronbiol sales in Q2 and beyond considering their Q1 windfall.
"In 2023, we sold just under $100,000 of this product, mostly for partner R&D. At this point, in 2024, we have already shipped this product to 3 customers and our sales and open orders are already over $1.5 million."
Also, they were very clear to point out what the combined facilty value was, which is a first.
Recall that we have $18 million of cash at year-end and less than $3 million of debt with full ownership of our $20 million to $25 million in real estate assets, including production facilities in Barrie, Ontario; Napanee, Ontario; and Hope, BC.
Management are finally starting to wave the Medipharm pom poms which is also a really nice change for Labs shareholders.